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Abstract: Four new indole alkaloids, plasiaticines A–D (1–4), together with two known ones, were isolated from the seeds of  
Plantago asiatica. The structures of the new compounds were elucidated on the basis of comprehensive analysis of spectroscopic 
data. All compounds were tested for their cytotoxic activity, and all compounds except 4 were tested for their acetylcholinesterase 
(AChE) inhibitory activities. 
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Introduction 
Most species of Plantago genus are perennial herbs widely 
distributed in China, and the aerial parts of many Plantago 
species have been used as diuretic,1 expectorant,2 anti-
inflammatory agent3 in folk medicine for a long time.  
Phytochemical research found that this genus produced poly-
saccharides,4,5 flavonoids,6–8 caffeic acid glycoside esters,9,10 
phenylethanoid glycosides,5,10–12 iridoid glucosides,13–17 and 
triterpene acids,8,18,19 which showed various bioactivities, such 
as anti-inflammatory,20 antibacterial,21,22 antioxidant,11,23  
immunesuppressant,24 analgesic,25 and antiallergic activity.7,26 
The seeds and whole plants of P. asiatica are recorded in 
Pharmacopoeia of People’s Republic of China.27 Previous 
studies on P. asiatica have led to the identification of several 
kinds of components, including polysaccharides,4,5  
phenylethanoid glycosides,5,10–12 and phenolic constituents.28 
Polysaccharides from the seeds of P. asiatica were found to 
enhance the immune function of the immunosuppressant mice 
in the previous study.29 Motivated by a search for bioactive 
metabolites from seeds of this plant, an investigation of the 
chemical constituents was carried out. As a result, four new 
indole alkaloids, plasiaticines A–D (1–4), along with two  
analogues (5 and 6), were isolated. Among them, compound 5 
was firstly isolated from natural source. In this paper, we  
report the isolation, structure determination, cytotoxic activity 
and AChE inhibitory activity of these compounds. 
 
Results and Discussion 
A 70% aqueous acetone extract of the seeds of P. asiatica 
was partitioned between EtOAc and H2O. The EtOAc solubles 
were dried and subjected to silica gel, Sephadex LH-20 and 
Lichroprep RP-18 gel column chromatography (CC) and 
semipreparative HPLC to afford four new compounds, 
plasiaticines A–D (1–4), together with two known ones, (+)-
(R)-3-cyanomethyl-3-hydroxyoxindole (5),30,31 and indolyl-3-
carboxylic acid (6).32 
Compound 1 was obtained as colorless oil and had the 
molecular formula of C12H11NO4 as determined by the analysis 
of its NMR spectroscopic data and verified by HREIMS 
(found m/z 233.0687, calcd for 233.0688), requiring eight 
degrees of unsaturation. The IR spectrum exhibited absorption 
bands for hydroxy (3423 cm–1) and γ-lactone carbonyl (1789 
cm–1) groups and an aromatic ring (1499 and 1475 cm–1). The 
UV spectrum displayed absorption maximum at 309, 261 and 
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207 nm. These characteristic IR and UV absorptions indicated 
1 was an oxindole-type compound.33,34 The 1H NMR 
spectroscopic data (Table 1) showed one set of 1,3,4-
trisubstituted benzene protons, one oxygenated methine group 
connecting with a methyl, and two methylene protons 
neighboring a carbonyl group. The 13C NMR and DEPT 
spectra (Table 2) showed one methyl, one methylene, four 
methines (one oxygenated and three olefinic), and six 
quarternary carbons (two carbonyls and three olefinic ones). 
Apart from an oxindole core and a carbonyl, the remaining one 
degree of unsaturation of 1 was determined to be a lactone 
skeleton. One pair of methylene protons [δH 3.06 (d, J = 17.1 
Hz, H-8), 2.76 (d, J = 17.1 Hz, H-8)] presenting AB system 
suggested that the C-3 to be a spiro-quarternary carbon. This 
was further confirmed by HMBC correlations of of H-8 with 
C-2, C-3, C-9 and C-10, and of H-11 with C-3 and C-10 
(Figure 1), together with 1H-1H COSY correlation of H-10/H-
11 (Figure 1). These evidence suggested that compound 1 
might have the same structure core as that of coixspirolactam 
B.35 Comparison of the NMR data of 1 with those of 
coixspirolactam B showed that the difference could be 
rationalized to the replacement of a hydroxy group substituted 
at C-5. This was further confirmed by HMBC correlations of 
H-4 with C-3a, C-5 and C-7a, of H-6 with C-4 and C-5, of H-7 
with C-3a, C-5 and C-7a (Figure 1), together with 1H-1H 
COSY correlations of H-6/H-7 and H-10/H-11 (Figure 1).  
The relative configurations of 1 were determined by 
correlations of H-4/H-8a and H-4/H-10; and of H-8a/H-10 in 
ROESY experiment (Figure 2), which showed that 1 also 
possessed the same relative configurations as those of 
coixspirolactam B.35 
On the base of the relative configurations of compound 1 
established by ROESY spectrum, the absolute configurations 
of 1 were determined by the theoretical calculation method of 
the ECD spectra by using time-dependent DFT (TDDFT) 
method in B3LYP/6-31G+(d,p) level. The calculated ECD 
curve for 3S,10R stereoisomer of 1 was similar to the 
experimental one (Figure 3). In addition, molecular orbital 
(MO) analysis of the dominant conformer 1b with 64.7% 
population in MeOH gave us more information to understand 
the experimental ECD spectrum of 1. The negative Cotton 
effect (CE) at 225 nm resulted from the negative rotatory 
strength at 214 nm involving a π→π* electronic transition 
from MO61 to MO67 (Figure 4). Consequently, the absolute 
configuration of 1 was determined to be 3S,10R. Therefore, 
compound 1 was established as shown and named plasiaticine 
A. 
The molecular formula of 2 was deduced as C10H8N2O3 
from its HREIMS (m/z 204.0546, calcd for 204.0535) and 1H 
and 13C NMR data, corresponding to eight degrees of 
unsaturation. Comparisons of these characteristic IR and UV 
absorptions with those of 1 indicated that 2 was also an 
oxindole-type compound.33,34 The NMR data (Tables 1 and 2) 
suggested that 2 had the same oxindole moiety as that in (+)-
(R)-3-cyanomethyl-3-hydroxyoxindole (5).30,31 The structural 
difference between 2 and 5 was an additional hydroxy at C-5 
in 2, which was further confirmed by the HMBC correlations 
(Figure 1). 
The calculated ECD curve for the 3R stereoisomer of 2 was 
compared to the experimental one, suggesting that the 
calculated ECD curve corresponded well with the 
 
Figure 1.  Key HMBC (H C) and 1H-1H COSY (▬) 
correlations of 1 and 2 
 
Figure 2.  Key ROESY (H H) correlations of 1 and 2 
Table 1. 1H NMR data of 1–4 (δ in ppm, J in Hz) 
pos. 1a 2b 3c 4d 
1 8.26 (br. s) 11.77 (br. s) 11.86 (br. s) 12.69 (br. s) 
4 7.07 (d, 1.8) 7.93 (br. s) 7.90 (d, 8.1) 7.63 (d, 7.2) 
5   6.90 (dd, 8.1, 1.6) 7.07 (t, 7.8) 
6 6.75 (br. dd, 
8.4, 1.8) 
6.94 (d, 7.0)  7.17 (d, 8.4) 
7 6.79 (d, 8.4) 7.15 (d, 7.0) 6.83 (d, 1.6)  
8a 3.06 (d, 17.1) 3.61 (d, 16.4) 3.60 (d, 16.4) 3.64 (d, 16.8) 
8b 2.76 (d, 17.1) 3.30 (d, 16.4) 3.20 (d, 16.4) 3.30 (d, 16.8) 
10 4.81 (q, 6.4)    
11 1.22 (d, 6.4)    
aRecorded at 400 MHz in acetone-d6; bRecorded at 400 MHz in 
pyridine-d5; cRecorded at 500 MHz in pyridine-d5; dRecorded at 
600 MHz in pyridine-d5. 
Table 2. 13C NMR data of 1–4 (δ in ppm) 
pos. 1a 2b 3c 4d 
2 178.2 s 178.7 s 179.4 s 179.3 s 
3 55.7 s 73.8 s 73.4 s 74.5 s 
3a 129.6 s 132.5 s 121.4 s 133.0 s 
4 112.3 d 113.4 d 126.2 d 116.2 d 
5 154.2 s 155.0 s 109.7 s 123.7 d
6 116.0 d 117.2 d 161.2 s 118.3 d 
7 111.2 d 111.6 d 99.6 d 144.0 s 
7a 135.4 s 134.5 s 144.5 s 131.5 s 
8 39.2 t 27.8 t 27.9 t 28.2 t 
9 174.3 s 117.9 s 117.9 s 118.3 s 
10 82.1 d    
11 14.7 q    
aRecorded at 100 MHz in acetone-d6; bRecorded at 100 MHz in 
pyridine-d5; cRecorded at 125 MHz in pyridine-d5; dRecorded at 
150 MHz in pyridine-d5. 
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experimental one except for a little red-shift in the calculated 
ECD spectrum (Figure 5). Furthermore, MO analysis of the 
dominant conformer 2e with 70.2% population in MeOH 
afforded comprehension of the experimental ECD spectrum of 
2. The electronic transitions from MO53 to MO58 involving a 
π→π* transition gave rise to the positive rotatory strength at 
217 nm, which could be assigned to the experimental positive 
CE at 211 nm. The electronic transitions from MO51 to MO54 
resulted in the negative rotatory strength at 239 nm, 
contributing to the negative CE at 238 nm. The positive 
rotatory strength at 260 nm resulted from the electronic 
transitions from MO53 to MO55 involving a π→π* transition, 
which correlated to the weak positive CE at 267 nm (Figure 6). 
Thus, the absolute configuration of 2 was established as shown 
and named plasiaticine B. 
Compounds 3 and 4 were both isolated as colorless oil and 
had the same molecular weight as 2. Detailed comparison of 
the NMR spectra led to the conclusion that the only difference 
among compounds 2, 3 and 4 was the location of the hydroxy 
group on the aromatic ring. In compound 3, the hydroxy group 
was substituted at C-6, which could be elucidated by 1H-1H 
COSY correlation of H-4/H-5, and by HMBC correlations of 
H-4 with C-3, C-5, C-6, C-7a; of H-5 with C-3a, C-4, and C-6; 
and of H-7 with C-3a, C-5, C-6, and C-7a. In compound 4, the 
hydroxy was located at C-7. This could be further confirmed 
by 1H-1H COSY correlations of H-4/H-5/H-6, and by HMBC 
correlations from H-4 to C-3, C-6 and C-7a; from H-5 to C-3a 
and C-7; and from H-6 to C-4, C-5 and C-7. Their absolute 
structures were also determined by analysis of their CD 
spectra. The CD spectra of 3 and 4 were both consistent with 
that of 2 (Figures 24S and 32S in Electronic Supplementary 
Material). This evidence determined the absolute configuration 
of C-3 in both 3 and 4 were also determined to be R, as well. 
All compounds were assayed for their cytotoxicity against 
the HL-60, SMMC-7721, A-549, MCF-7, and SW-480 human 
tumor cell lines by the MTS method with cisplatin and taxol as 
positive controls.36 However, no compound showed significant 
activity with IC50 more than 40 μM. Compounds 1–3, 5 and 6 
were evaluated for their inhibitory activities against AChE, 
with tacrine as a positive control.37 None of them showed  
inhibitory activity against AChE with the inhibition ratio less 
than 60%. Compound 4 was not further tested for its AChE 
inhibitory activity due to the limited amount available. 
 
Experimental Section 
General Experimental Procedures. Optical rotations were 
measured with a JASCO DIP-370 digital polarimeter. UV 
spectra were obtained using a Shimadzu UV-2401A spectro-
photometer. A BioRad FtS-135 spectrophotometer was used 
for scanning IR spectroscopy with KBr pellets, whereas CD 
spectra were recorded on a JASCO J-810 spectropolarimeter. 
1D and 2D NMR spectra were recorded on Bruker AM-400, 
DRX-500 and Bruker Avance III-600MHz spectrometers. 
Unless otherwise specified, chemical shifts () were expressed 
in ppm with reference to the solvent signals. High-resolution 
electron impact mass spectra (HREIMS) were performed on a 
VG Autospec-3000 spectrometer under 70 eV. Column  
chromatography was performed using silica gel (80–100 and 
200–300 mesh, Qingdao Marine Chemical, Inc., Qingdao, 
China). Semi-preparative HPLC was performed on an Agilent 
1100 liquid chromatograph with a Zorbax SB-C18, 9.4 mm  
25 cm, column. Fractions were monitored by TLC and spots 
were visualized by heating the silica gel plates sprayed with 
10% H2SO4 in EtOH. 
 
Figure 3.  Experimental and calculated ECD spectra of 1 
 
MO61 MO67 
Figure 4.  The most important orbitals involved in the key 
transitions of the conformer 1b at B3LYP/6-31+G(d,p) level 
in MeOH with PCM model 
 
Figure 5.  Experimental and calculated ECD spectra of 1 
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Plant Material. The seeds of P. asiatica were purchased 
from Juhuacun Traditional Chinese Medicine Market,  
Kunming, Yunnan Province, China, in August 2011. A voucher
specimen (No. KIB 2011-08-11) has been deposited at the 
State Key Laboratory of Phytochemistry and Plant Resources 
in West China, Kunming Institute of Botany, Chinese Academy
of Sciences. 
 
Extraction and Isolation. The air dried seeds of P. asiatica 
(10 kg) were extracted with 70% aqueous acetone (3 × 30 L, 
three days each) at room temperature. The solvent was  
removed in vacuo to afford a crude extract, which was  
dissolved in H2O, and then extracted successively with EtOAc 
(1:1) and n-BuOH for three times, respectively. The EtOAc-
soluble part (285 g) was subjected to silica gel column  
chromatography (silica gel, 80–100 mesh, CHCl3/Me2CO, 1:0, 
9:1, 8:2, 7:3, 6:4 and 0:1 ) to afford fractions A–E. Fraction C 
was chromatographed on RP-18 gel and eluted with 
MeOH/H2O (30/70–100/0) to give five subfractions C1–C5. 
Subfraction C1 was further purified with repeatedly silica gel 
(200–300 mesh, petroleum ether/acetone), Sephadex LH-20 
(MeOH) and followed by semipreparative HPLC (MeOH/H2O, 
65/35) to afford compounds 1 (8 mg) and 6 (12 mg).  
Subfraction C3 was purified by repeated chromatography on 
silica gel and then on semipreparative HPLC (MeOH/H2O, 
60/40) to give compounds 2 (12 mg), 3 (11 mg), 4 (3 mg), and 
5 (11 mg). 
 
Plasiaticine A (1): colorless oil; [α] 23D   – 14.3 (c 0.08, 
MeOH); UV (MeOH) λmax (log ε) 207 (3.80), 261 (3.42), and 
309 (2.84) nm; IR (KBr) νmax 3423, 1789, 1766, 1704, 1499, 
1475, 1201 cm–1; 1H and 13C NMR data, see Tables 1 and 2; 
positive ESIMS m/z 256 (100) [M + Na]+; HREIMS m/z 
233.0687 [M]+ (calcd for C12H11NO4, 233.0688). 
 
Plasiaticine B (2): colorless oil; [α] 23D   + 18.1 (c 0.13, 
MeOH); UV (MeOH) λmax (log ε) 208 (3.34), 264 (2.92), and 
315 (2.31) nm; IR (KBr) νmax 3425, 2262, 1721, 1628, 1478, 
1202 cm–1; 1H and 13C NMR data, see Tables 1 and 2; positive 
ESIMS m/z 227 (100) [M + Na]+; HREIMS m/z 204.0546 
[M]+ (calcd for C10H8N2O3, 204.0535). 
 
Plasiaticine C (3): colorless oil; [α] 23D   + 88.7 (c 0.10, 
MeOH); UV (MeOH) λmax (log ε) 216 (3.81), and 271 (2.93) 
nm; IR (KBr) νmax 3428, 2260, 1725, 1632, 1472, 1117 cm–1; 
1H and 13C NMR data, see Tables 1 and 2; EIMS m/z 204 [M]+; 
HREIMS m/z 204.0506 [M]+ (calcd for C10H8N2O3, 204.0535). 
 
Plasiaticine D (4): colorless oil; [α]25D   + 5.2 (c 0.20, MeOH); 
UV (MeOH) λmax (log ε) 214 (3.32), and 306 (2.57) nm; IR 
(KBr) νmax 3443, 2263, 1721, 1631, 1492, 1384 cm–1; 1H and 
13C NMR data, see Tables 1 and 2; EIMS m/z 204 (100) [M]+; 
HREIMS m/z 204.0538 [M]+ (calcd for C10H8N2O3, 204.0535). 
 
ECD Calculation. The theoretical calculations of 
compounds 1 and 2 were performed using Gaussian 09.38 
Conformational analysis was initially carried out using 
Maestro7.5 conformational searching, together with the 
OPLS_2005 molecular mechanics methods. The optimized 
conformation geometries, thermodynamic parameters, and 
populations of all conformations were provided in the  
Electronic Supplementary Material (Figures 8S and 16S, and 
Tables 1S to 4S, and 5S to 8S). Then the OPLS_2005 
conformers were then optimized at B3LYP/6-31G(d) level. 
The room temperature equilibrium populations were calculated 
according to Boltzmann distribution law. The ECD was 
  
 
MO51 MO52 MO53 
 
 
MO54 MO55  
Figure 6.  The most important orbitals involved in the key transitions of the conformer 2e at B3LYP/6-31+G(d,p) level in MeOH 
with PCM model 
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performed at B3LYP/6-31G+(d,p) level in MeOH with PCM 
model. The ECD spectra of compounds 1 and 2 were obtained 
by weighing the Boltzmann distribution rate of each geometric 
conformation. 
 
ECD Simulation. The ECD spectra were simulated by 













   
The σ represented the width of the band at 1/e height, and 
ΔEi and Ri were the excitation energies and rotatory strengths 
for transition i, respectively. σ = 0.20 eV and Rvelocity had been 
used in this work. 
 
MO Analysis. The orbital information (NBO plot files) was 
generated by NBO program39 of Gaussian 09. The dominantly 
populated conformers were selected to molecular orbital (MO) 
analysis. The NBO plot files were used to generate 
corresponding Gaussian-type grid file by Multiwfn 2.4.40 After 
that, the isosurface of generated grid date was generated by 
VMD software.41 
 
Cytotoxicity Assay. The following human tumor cell lines 
were used: HL-60, MMC-7721, A549, MCF-7, and SW480. 
All cells were cultured in RPMI-1640 or DMEM medium 
(Hyclone, Logan, UT), supplemented with 10% fetal bovine 
serum (Hyclone) at 37 C in a humidified atmosphere with 5% 
CO2. Cell viability was assessed by conducting colorimetric 
measurements of the amount of insoluble formazan formed in 
living cells based on the reduction of 3-(4,5-dimethylthiazol- 
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetra-
zolium (MTS) (Promega).36 Briefly, 100 μL of adherent cells 
was seeded into each well of a 96-well cell culture plate and 
allowed to adhere for 12 h before drug addition, while 
suspended cells were seeded just before drug addition, both 
with an initial density of 5 × 103–1 × 104 cells/mL in 100 μL 
of medium. Each cell line was exposed to the test compound at 
various concentrations in triplicate for 48 h, with cisplatin 
(Sigma) and taxol (Sigma) as positive controls. After the 
incubation, the medium containing compounds was removed , 
and the cells were incubated for 1–4 h at 37 C in the dark 
with 20 μL of the MTS reagent diluted in 100 μL of culture 
medium. The optical density was measured at 490 nm in a 96-
well microtiter plate reader (Bio-Rad 680). The IC50 value of 
each compound was calculated by Reed and Muench’s 
method.42 
 
Acetylcholinesterase Inhibitory Activity Assay. Acetyl-
cholinesterase (AChE) inhibitory activity of the compounds 
isolated was assayed by the spectrophotometric method  
developed by Ellman37 with slightly modification. S-acetyl-
thiocholine iodide, 5,5ꞌ-dithio-bis-(2-nitrobenzoic) acid (DTNB,
Ellman’s reagent), and acetylcholinesterase derived from  
human erythrocytes were purchased from Sigma Chemical. 
Compounds were dissolved in DMSO. The reaction mixture 
(totally 200 μL) containing phosphate buffer (pH 8.0), test 
compound (50 μM), and acetyl cholinesterase (0.02 U/mL) 
was incubated for 20 min (30 °C). Then, the reaction was  
initiated by the addition of 40 μL of solution containing DTNB 
(0.625 mM) and acetylthiocholine iodide (0.625 mM) for 
AChE inhibitory activity assay. The hydrolysis of  
acetylthiocholine was monitored at 405 nm every 3 minutes 
for one hour. Tacrine was used as positive control with final 
concentration of 0.333 μM. All the reactions were performed 
in triplicate. The percentage inhibition was calculated as  
follows: % inhibition = (E – S)/E × 100 (E is the activity of 
the enzyme without test compound and S is the activity of 
enzyme with test compound). 
 
Electronic Supplementary Material 
Supplementary material is available in the online version of 
this article at http://dx.doi.org/ 10.1007/s13659-012-0082-4 
and is accessible for authorized users. 
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